enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01 2월 2025 - 6:05AM
Business Wire
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”),
a clinical-stage genetic medicines company whose non-viral lead
investigational product detalimogene voraplasmid, (also known as
detalimogene, and previously EG-70), is in an ongoing pivotal study
in patients with high-risk, Bacillus Calmette-Guérin
(BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with
carcinoma in situ (CIS), today reported the grant of inducement
equity awards to seven newly-hired employees, with a grant date of
January 29, 2025.
The inducement awards consist of a non-qualified stock options
to purchase an aggregate 262,900 of the Company's common shares.
The options each have an exercise price of $7.39 per share, which
is equal to the closing price of the Company's common shares on
January 29, 2025, the date of grant. Each stock option has a
10-year term and will vest over four years, with 25% of the
underlying shares vesting on the one-year anniversary of the
employee’s employment commencement date and the remainder vesting
in equal amounts monthly for three years thereafter, subject to the
employee’s continued service as an employee of, or other service
provider to, the Company through the applicable vesting dates.
The stock options were granted by the Company's independent
Compensation Committee of the Board of Directors as an inducement
material to each new employee entering into employment with the
Company in accordance with NASDAQ Listing Rule 5635(c)(4). While
the stock options were granted outside of the Company’s Amended and
Restated enGene Holdings Inc. 2023 Incentive Equity Plan (Plan),
each option will have terms and conditions consistent with those
set forth under the Plan.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming
genetic medicines through the delivery of therapeutics to mucosal
tissues and other organs, with the goal of creating new ways to
address diseases with high clinical needs. enGene’s lead program is
detalimogene voraplasmid (also known as detalimogene, and
previously EG-70) for patients with Non-Muscle Invasive Bladder
Cancer (NMIBC), a disease with a high clinical burden. Detalimogene
is being evaluated in the ongoing multi-cohort LEGEND Phase 2
study, which includes a pivotal cohort studying detalimogene in
Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma
in situ (CIS). Detalimogene was developed using enGene’s
proprietary Dually Derivatized Oligochitosan (DDX) platform, which
enables penetration of mucosal tissues and delivery of a wide range
of sizes and types of cargo, including DNA and various forms of
RNA. For more information, visit enGene.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250131922136/en/
For media contact: 908-577-4531 mediainquiries@grcomms.com For
investor contact: investors@engene.com
enGene (NASDAQ:ENGN)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
enGene (NASDAQ:ENGN)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
